複雑性尿路感染症に対するCeftizoxime (FK 749)の臨床的検討

Abstract

複雑性尿路感染症63例にceftizoximeを投与した.UTI薬効評価基準に準じて判定した20例の臨床効果は, 有効率80%であった.副作用は, 血液検査値の軽度の一過性上昇例, ショック症状を呈した症例を, それぞれ1例ずつ経験した

The clinical effectiveness and safety of Ceftizoxime were evaluated in 63 patients with complicated urinary tract infection. Out of 20 patients evaluated by the UTI criteria, the results were excellent in 4 cases (20%), moderate in 12 cases (60%) and poor in 4 cases (20 %). The clinical efficacy was satisfactory even in the cases with indwelling catheter, as well as in the cases without catheter. Response to bacteriuria was studied in 31 cases. Out of 40 strains isolated before treatment, 33 strains (82.5%) were eradicated. From the above results, Ceftizoxime is considered to be a useful antibiotic in the treatment of complicated urinary tract infection. Adverse effects were experienced in 2 of the 63 cases studied. One patient showed transient elevation of BUN, creatinine, bilirubin and GOT, all of which returned to normal after discontinuation of drug administration. Anaphylactic shock developed in another patient, who recovered soon after treatment. This case was thought to be an exceptional case because of the patient's history and the fact that no incidence of shock with the use of the drug has been reported.